LYON, FRANCE--Biom’Up, a young company specialized in the manufacture of re-absorbable medical devices, announces today that it has raised EUR 6.8 million in new funds from existing shareholders and acquired three new investors: the InnoBio fund, managed by CDC Entreprises under the ‘FSI France Investissement’ program, Viveris Management and OTC Asset Management.
Tuesday, October 30, 2012
SANTA CLARA, CALIF.--Agilent Technologies Inc. (NYSE: A) today announced the opening, at the University of Leeds, of the first Agilent-equipped terahertz measurement laboratory in Europe. The new laboratory will enable research on devices, components, circuits and systems at much higher frequencies than any other institution in the region has been able to do before. The lab is set up in memory of professor Roger Pollard, former dean of engineering at the University of Leeds and a long-time friend of Agilent, who passed away at the end of last year. The Agilent 1.1-THz PNA network analyzer is the centrepiece of the new lab.
Thursday, October 25, 2012
TAIPEI, TAIWAN--GlacialLight, a division of the Taiwanese technology manufacturer, GlacialTech Inc., has added the GL-FL30-V2, a 27W AC-input LED Flood Light with Philips Lumileds LED chips, to its energy efficient and light-weight flood light series.
Pfenex Inc. Awards Althea Technologies a Contract for cGMP Manufacturing of Circumsporozoite Protein
SAN DIEGO, CALIF.--Pfenex Inc. today announced that it has awarded Althea Technologies a contract for the current Good Manufacturing Practice (cGMP) manufacturing of circumsporozoite protein (CSP) from Plasmodium falciparum, an important and proven component of an effective malaria vaccine. Althea Technologies will implement the cGMP-ready Pfēnex Expression Technology™-based production process that was developed at Pfenex over the past several months. Processes for several additional malaria antigens are currently being developed at Pfenex.
VALBONNE, FRANCE--TxCell SA, a biotechnology company developing cell-based immunotherapies for the treatment of severe chronic inflammatory diseases with high unmet medical need, announces today the publication of the complete results of CATS1 Crohn’s disease study in Gastroenterology, the most prominent journal in the field of gastrointestinal disease, and the presentation of the long term treatment extension data at UEGW, the main European gastroenterology meeting.
JERUSALEM--BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, announced today that it intends to conduct an interim analysis of the Phase II/III CLARITY trial of BL-1020, a first in class, orally available, GABA-enhanced antipsychotic for the treatment of schizophrenia. The interim analysis, which is expected to be finalized in the first quarter of 2013, will be performed on data of approximately 235 randomized patients from 27 sites in Romania and India. The primary endpoint of the analysis will be the six-week effect of the drug on cognitive function, which is a principal deficit in schizophrenia patients.
Wednesday, October 24, 2012
TRENTON, N.J.--Patients who use respiratory inhalers will be able to recycle the devices for the first time in the U.S., according to British drugmaker GlaxoSmithKline PLC, which is launching its "Complete the Cycle" program Wednesday in drugstores in 31 cities. GlaxoSmithKline is the top seller of respiratory medicines in the U.S., with brands including the blockbuster Advair, but its new program will also recycle inhalers made by competitors. The program, starting in cities from Anchorage, Alaska, to Atlanta, will enable patients to drop off inhalers in boxes at participating pharmacies. When bags inside the boxes are full, they'll be shipped to a Glaxo recycling contractor.
BARCELONA, SPAIN--Almirall (ALM.MC), the international pharmaceutical company headquarted in Barcelona, has reached an agreement with the Spanish biotech company AB-Biotics (ABB.MC) to enter the share capital of the company listed on the Spanish Alternative Investment Market (MAB). This operation enables Almirall to complement its commitment to innovation through pharmacogenetics and personalised medicine, one of the specialist areas of AB-Biotics.
SANTA CLARA, CALIF.--Agilent Technologies Inc. (NYSE: A) today announced it will demonstrate next-generation test and measurement solutions that are enabling future communications systems, including satellite and military radio test solutions, MIMO, multi-tone, group delay and wideband chirp test applications, and handheld instruments, at MILCOM (Gaylord Palms Resort and Convention Center, Booth 530), in Kissimmee, Fla., Oct. 29- Nov. 1.
PARIS, FRANCE--Cytheris SA, a clinical-stage biopharmaceutical company focused on treating lymphopenia driven diseases, announces today that the US Food and Drug Administration (FDA) has granted an Orphan Drug Designation for Cytheris’ CYT017, glycosylated recombinant human interleukin-7 (glycosylated r-h-IL7), for the treatment of Progressive Multifocal Leukoencephalopathy (PML). This designation from the FDA follows orphan drug designation for the same indication granted in Europe in July 2012 from the European Commission.
Tuesday, October 23, 2012
Largest Independent Patent Law Firm in the Carolinas Hosts Reception with Clients and Peers, Continues to Present at Industry Events
RALEIGH, N.C.--Myers Bigel Sibley & Sajovec, P.A. (Myers Bigel), the largest independent patent law firm in the Carolinas, recently celebrated 15 years of excellence in intellectual property protection with a reception for clients, peers, and staff outside its office on Parklake Avenue in Raleigh. The celebration marked continuing growth in terms of clients, practicing attorneys, industry leadership and third-party accolades attesting to the firm’s success in filing, defending, and enforcing intellectual property, with a strong focus on patents. "We continue to invest in dedicated patent lawyers with technical degrees who are eager to produce and enforce top-quality patents," Jim Cannon, managing partner and member of Myers Bigel's mechanical group, said.
STRASBOURG, FRANCE--Domain Therapeutics S.A. announced today that Domain Therapeutics and Ono Pharmaceutical Co., Ltd. (Osaka, Japan) signed a collaboration agreement focused on discovering small molecules targeting G-Protein Coupled Receptors (GPCRs). Under the agreement, Ono will provide Domain Therapeutics with an upfront payment, pay research funding for the collaborative research programs and success-based milestones on the research and development progress, as well as royalties on sales of the products.
NES ZIONA, ISRAEL--BiondVax Pharmaceuticals Ltd. (TASE: BNDX) announced that the Company has passed successfully a 2 day QP GMP audit during which the Company`s manufacturing facility, production process, personnel and quality control procedures were examined in great detail. This demanding certification is a requirement for companies intending to manufacture a clinical grade product for human trials anywhere in Europe and gives the Company the go-ahead to advance clinical development of its universal flu vaccine, M-001, in the EU.
Thursday, October 18, 2012
DECATUR, ALA.--October 18, 2012 - 3-GIS, a GIS software solutions company based in Decatur, Alabama and Survey And Mapping, Inc. (SAM, Inc.), a nationally recognized provider of geospatial data services, headquartered in Austin, Texas, have announced a strategic partnership that will allow SAM, Inc. to resell 3-GIS software solutions.
NEW YORK, N.Y.--Sharp® Electronics Corporation, the US marketing and distribution subsidiary of Sharp corporation, known worldwide for its Aquos® TVs, professional displays, projectors, printers and copier solutions, has recently launched a Turn-Key Digital Signage Package. The package includes access to EnGage from ComQitm, the global multi-channel message management company. It also includes Sharp® commercial display products and related hardware components as well as a content starter pack for fast, effortless implementation.
SAN DIEGO, CALIF--Cebix is moving ahead in its development of C-peptide replacement therapy for treating diabetes-related microvascular problems. Encouraging results from an early stage trial, reported earlier this month at the annual meeting of the European Association for the Study of Diabetes, have led the company to raise an additional $30.9 million and to recruit veteran local biotech executive Joel Martin as CEO.
WHITEHOUSE STATION, N.J.--Merck & Co. is paying Theravance $5 million up front as part of a collaboration agreement focused on developing novel small molecule therapeutics against a candidate hypertension and heart failure target. The deal gives Merck a worldwide, exclusive license to Theravance’s therapeutic candidates, in return for the up-front payment, research funding, and potential milestone payment of up to $148 million for the first indication, plus royalties on worldwide net sales of relevant products. The deal comes less than two weeks after Theravance inked a co-development and licensing option deal with Alfa Wassermann for its clinical-stage 5-HT4 antagonist velusetrag, for the treatment of gastrointestinal motility disorders.
Wednesday, October 17, 2012
ST. PAUL, MINN.--A new website for label sensor users, labelsensors.com, promises to make it easier to choose and use the right label sensor. In the current market, many different label sensor technologies are available, each with its own strengths and weaknesses. Because label sensors are such a small part of a complete packaging system, users don’t devote a lot of time to search out all the possibilities, understand them, and make the best selection; labelsensors.com collects all of that information and organizes it so a visitor can quickly compare the strengths and weaknesses of each type of sensor and choose the best technology for a specific application.
ARLINGTON, VA.--The mHealth Summit today announced that Mark T. Bertolini, Chairman, Chief Executive Officer and President of Aetna, will deliver the opening keynote address at this year’s event. The 4th annual mHealth Summit will take place December 3-5, 2012 at the Gaylord National Resort and Convention Center in the Washington, DC area. Mr. Bertolini will address attendees at 9:15 a.m. on Monday, December 3rd. In his keynote, he will share his personal passion for creating a connected, convenient health care system that empowers patients to take control of their health. In addition, Mr. Bertolini will demonstrate how Aetna is using innovative technology to bring this connected, convenient system to life.
WINTERTHUR, SWITZERLAND--Spinelab Ltd., a privately held company, that develops innovative spinal treatment concepts, specializing in motion preserving stabilization systems, and Biomet EMEA, a division of Biomet, Inc., a global leader in the manufacture of musculoskeletal medical products, announced today the signature of an exclusive distribution agreement. Under the agreement, Biomet will have exclusive distribution rights for Spinelab’s pedicle screw based posterior elastic stabilization system Elaspine™ in Spain and Portugal.
SAN DIEGO, CALIF.--Pfenex Inc. today announced that the National Institute of Allergy and Infectious Diseases (NIAID) under its Broad Agency Announcement entitled “Vaccine Technologies to Advance Next Generation Anthrax Vaccines” (BAA-NIAID-DMID-NIHAI2010104) has awarded Pfenex a contract to develop an alternative delivery method for Pfenex’s recombinant Protective Antigen (rPA)-based anthrax vaccine. NIAID, part of the National Institutes of Health, has made an initial award of $2.18 million to Pfenex with further funding of up to a total of $22.9 million available over the course of the contract if all options are exercised.
RESEARCH TRIANGLE PARK, N.C.--The pharmaceutical industry’s go-to resource for pharmacokinetics (PK), ClinPharm Consulting, LLC, is sharing its in-depth knowledge of how to use PK to make better decisions faster at a key gathering of pharmaceutical scientists in Chicago October 15-18. ClinPharm will be exhibiting at the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting, following the firm’s recent participation in September’s Annual Meeting of the American College of Clinical Pharmacology (ACCP).
Tuesday, October 16, 2012
WILMINGTON, DEL.--A123 Systems Inc. (AONE), a maker of rechargeable lithium-ion batteries for electric cars, filed for bankruptcy after failing to make a debt payment that was due yesterday. A123, which received a $249.1 million federal grant in 2009 to build a U.S. factory, needed a financial lifeline after struggling with costs from a recall of batteries supplied to Fisker Automotive Inc., the plug-in hybrid luxury carmaker. A123 announced in August that it was working on a deal with Wanxiang Group Corp., China’s largest auto-parts maker, for financing in exchange for a majority ownership stake. The company listed assets of $459.8 million and debt of $376 million as of Aug. 31 in Chapter 11 documents filed today in U.S. Bankruptcy Court in Wilmington, Delaware. Chapter 11 is the section of the Bankruptcy Code used by companies to reorganize. A123 didn’t expect to be on time with an interest payment due yesterday on $143.8 million of notes expiring in 2016, or to make a payment due yesterday on $2.76 million in outstanding 6 percent notes, the Waltham, Massachusetts-based company said yesterday in a regulatory filing.
BioLineRx Announces Successful Completion of Pre-Clinical Development for BL-8020, an Oral, Interferon-Free Treatment for Hepatitis C
JERUSALEM--BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, announced today that it has successfully completed the pre-clinical development of BL-8020, an orally available, interferon-free treatment for the Hepatitis C virus (HCV), and plans to commence a Phase I/II safety and efficacy study for BL-8020 in Europe during the first quarter of 2013.
LARAMIE, Wyo.--Wyoming-based global company WellDog has commercialized an innovative coal gas testing technology which, for the first time, will allow mining companies to accurately detect and map underground gas characteristics before mining without drilling the extra wells required by slower and more expensive core sampling techniques.
NTT Communications Group Selects Vidyo and Arkadin for Breakthrough ‘Infrastructure-less’ Video Conferencing
PARIS & HACKENSACK, N.J.--Arkadin, one of the world’s largest collaboration service providers, and Vidyo, Inc., the first company to deliver personal telepresence, today announced that NTT Bizlink, Inc., a subsidiary of NTT Communications Corporation, has become one of the first carriers to provide video conferencing services through Vidyo’s infrastructure-less Vidyo As A Service program. This unique economic model enabled by Vidyo’s disruptive software-based hosted platform and delivered as a white label service by Arkadin, gives ICT service providers such as NTT Communications Group a fast and efficient way to broaden their offerings in the video conferencing market without requiring expensive upfront infrastructure investments.
RIVERSIDE, Calif.--Olfactor Laboratories, Inc. has advanced a world-class technology that could make mosquito bites a thing of the past and is preparing to take that technology to market as early as 2013. Following a two-year intensive collaboration with the University of California, Riverside, and a multinational pest control company, Olfactor announced its chemical technology can actually modify a mosquito’s biting behavior. This is a potential breakthrough in the battle against mosquito-borne diseases such as malaria and the West Nile virus.
BURLINGTON, Mass. & ANDOVER, Mass.--Infraredx, Inc., a medical device company committed to advancing the diagnosis and management of coronary artery and other vascular diseases, and Royal Philips Electronics (NYSE: PHG, AEX: PHIA) today announced they have signed a joint development and collaboration agreement that is focused on integrating Infraredx’s true vessel characterization (TVC) Imaging System with Philips’ Allura Xper catheterization (cath) lab imaging systems. This collaboration is intended to enable seamless access to the TVC Imaging System with Philips’ Allura X-ray systems.
Monday, October 15, 2012
MARSEILLE, FRANCE--Trophos SA, a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for indications with under-served needs in neurology and cardiology, announces today the award of a EUR 1 million grant to support the Translate-MS-Repair project.
SOUTH SAN FRANCISCO, Calif.--The Food and Drug Administration has approved a new use for a drug made by Roche division Genentech. The drug maker said Friday that the FDA had approved Actemra (tocilizumab) for adults with moderately to severely active rheumatoid arthritis who have not responded adequately to one or more disease-modifying antirheumatic drugs. The drug was already approved for systemic juvenile idiopathic arthritis.
Thursday, October 11, 2012
WASHINGTON, D.C.--Agriculture Secretary Tom Vilsack today announced that USDA will award matching grants for 22 projects under the Federal-State Marketing Improvement Program to help create economic opportunities for American farmers and ranchers. USDA will match nearly $1.2 million in grants for state departments of agriculture and state universities in 18 states and the District of Columbia. The projects will enable states to research new opportunities, and spark innovation in the marketing, transportation and distribution of U.S. agricultural products.
Miami, FL--Online auction site eBid (www.ebid.net) has hit 6.5 million live listings, for a gross value of $5 Billion in merchandise. This represents a 23% growth rate over 10 months, ever since hitting the significant milestone of five million listings in November, 2011. Founded in 1999 in the UK, eBid now spans a total of 23 territories, covering more than 100 countries and five continents.
DALLAS, TX--Social Commerce Innovator and Premium Digital Content for local television broadcast websites are a few of the trending industry phrases that describe HOTC Media Networks; yet today, the company is moving beyond words with its Official Social Communications Partner, Marketwire.
SANTA CLARA, CALIF.--Agilent Technologies Inc. (NYSE: A) today announced the latest release of its IO Libraries Suite 16.3 software for use with electronic test instruments. The new release continues to improve the customer experience, with support for Microsoft® Windows 8 and Windows Server 2012 as well as enhanced USB connections.
ZURICH, SWITZERLAND--Following the company’s mission, “Designing for Life,” Nobel Biocare continues its focus on helping dental professionals to treat more patients with superior solutions. At the 21st Annual Scientific Congress of the European Association of Osseointegration (EAO) in Copenhagen, Denmark, Nobel Biocare presents its latest product innovations, extensive clinical expertise and knowledge-building programs to support dental professionals in their patient treatment. For each step of the patient treatment flow – from diagnosis and treatment planning to surgery and finally prosthetic restoration – Nobel Biocare provides leading products and solutions to ensure maximum treatment safety, patient comfort and long-term success.
Wednesday, October 10, 2012
SANTA CLARA, Calif.--Agilent Technologies Inc. (NYSE: A) today announced that STMicroelectronics, a global semiconductor leader serving customers across the spectrum of electronics applications, has selected Agilent’s Electromagnetic Professional (EMPro) software for use in development of ESD structures based on advanced CMOS process technology.
EVREUS, FRANCE--CiToxLAB Group, a leading CRO in the field of non-clinical research, announces today that the group’s consolidated first half 2012 revenues reached EUR 37.2M (USD 48.4 million approximately). This marks a 34 per cent increase compared with the same period in 2011.
PARIS, FRANCE--Cytheris SA, a privately held clinical-stage biopharmaceutical company focused on treating lymphopenia driven diseases, announces today the publication of a paper demonstrating that Cytheris’ CYT107, glycosylated recombinant human interleukin-7 (glycosylated r-h-IL7) can enhance immune T cell recovery after a T cell-depleted (TCD) allogeneic hematopoietic stem cell transplantation (allo-HSCT). The study detailed in the paper demonstrated an increase in functional T cells, including viral-specific T cells that recognize CMV, and enhanced T cell receptor diversity. Additionally, there was no significant GVHD or other serious toxicity.
TALLASSEE, ALABAMA--Neptune Technology Group Inc. (“Neptune”) has partnered with both Esri®, the market-leading water utility geographic information system (GIS), and 3-GIS, the world’s leading browser-based GIS solutions provider, to enhance the mapping functionality within its advanced metering infrastructure (AMI) host software, N_SIGHT™ R45.
LAS VEGAS, NEVADA AND PALO ALTO, CALIF.--AlertID™ and the Alameda County Sheriff’s Office announced their partnership to make AlertID’s free mobile app and online public safety information services available to all county residents beginning today. The Alameda County Sheriff’s Office is the first agency in California to announce its partnership with AlertID, which will allow residents to receive the full range of AlertID apps and services at no cost to the public or the Sheriff’s office.
POMPEY, FRANCE--Novasep, a leading provider of purification-based manufacturing solutions for life science molecules, announces today an investment of EUR 30 million to build in Europe what will be the world's largest chromatography plant used for the production of a large volume commercial API (active pharmaceutical ingredient). The plant will be built on Novasep's existing Mourenx site in France and will be operational and validated within 18 months. Both the development of an advanced purification process and the plant expansion within the challenging timescale are results of the sharp increase in the projected demand for a large volume, highly purified API.
Tuesday, October 9, 2012
NEW YORK--Apalon is pleased to announce the release of the newly updated version of Weather Live, a universal weather app available now for iPhone 5. One of the best recognized names on the App Store, Weather Live delivers accurate and comprehensive forecasts for multiple locations accompanied with live weather scenes that reflect real-time weather conditions. The update leverages the new iPhone big screen and now looks beautiful and realistic like never before.
SAN FRANCISCO-- BMC Software (Nasdaq:BMC) today delivered major updates to its IT Service Management portfolio that enable organizations to transform their service desk into a flexible, proactive "genius bar" experience. As a result of BMC's transformative new approach to IT service delivery, IT organizations can transition quickly from a passive, infrastructure-oriented "support" function to one that delivers proactive, personalized enablement to today's highly mobile workforce.
JERUSALEM-- BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, announced today that a recent analysis of the results from the Phase IIb EAGLE trial for BL-1020, a first in class, orally available, GABA-enhanced antipsychotic for the treatment of schizophrenia, indicates that BL-1020 demonstrated a significant increase in efficacy at improving cognitive impairment associated with this condition, as compared to the original analysis of the study.